| Literature DB >> 24919805 |
A Porwit1, A A van de Loosdrecht2, P Bettelheim3, L Eidenschink Brodersen4, K Burbury5, E Cremers2, M G Della Porta6, R Ireland7, U Johansson8, S Matarraz9, K Ogata10, A Orfao9, F Preijers11, K Psarra12, D Subirá13, P Valent14, V H J van der Velden15, D Wells4, T M Westers2, W Kern16, M C Béné17.
Abstract
Definite progress has been made in the exploration of myelodysplastic syndromes (MDS) by flow cytometry (FCM) since the publication of the World Health Organization 2008 classification of myeloid neoplasms. An international working party initiated within the European LeukemiaNet and extended to include members from Australia, Canada, Japan, Taiwan and the United States has, through several workshops, developed and subsequently published consensus recommendations. The latter deal with preanalytical precautions, and propose small and large panels, which allow evaluating immunophenotypic anomalies and calculating myelodysplasia scores. The current paper provides guidelines that strongly recommend the integration of FCM data with other diagnostic tools in the diagnostic work-up of MDS.Entities:
Mesh：
Year: 2014 PMID： 24919805 DOI： 10.1038/leu.2014.191
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528